# A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

> **NCT01440374** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 162 (actual)

## Conditions studied

- Thrombocytopaenia

## Interventions

- **DRUG:** eltrombopag
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01440374
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-12
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01440374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01440374, "A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01440374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*